natgillin/translations-raw huggingface dataset:
Medicinal products used in the treatment of gout 
Zdravila za zdravljenje protina
MARKETING AUTHORISATION NUMBER(S) EU/1/08/491/060 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/08/491/060
• Low level of sodium in the blood 
• znižana raven natrija v krvi,
MARKETING AUTHORISATION NUMBER(S) EU/1/08/491/049 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/08/491/049
MARKETING AUTHORISATION NUMBER(S) EU/1/08/491/069 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/08/491/069
Musculoskeletal and connective tissue disorders Common 
Bolezni mišično-skeletnega sistema in vezivnega tkiva pogosti artralgijaa pogostnost neznana krči v mišicahh
This medicine is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed. 
Zdravljenje s tem zdravilom ni priporočljivo za doječe matere.
MARKETING AUTHORISATION NUMBER(S) EU/1/08/491/041 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/08/491/041
MARKETING AUTHORISATION NUMBER(S) EU/1/08/491/019 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/08/491/019
MARKETING AUTHORISATION NUMBER(S) EU/1/08/491/009 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/08/491/009
MARKETING AUTHORISATION NUMBER(S) EU/1/08/491/010 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/08/491/010
MARKETING AUTHORISATION NUMBER(S) EU/1/08/491/080 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/08/491/080
• Itching 
• driska,
• Abdominal discomfort 
• omotičnost,
Rasilez HCT should be discontinued if hypercalcaemia develops during treatment. 
Če pride med zdravljenjem do razvoja hiperkalciemije, je treba uporabo zdravila Rasilez HCT prekiniti.
• Dizziness 
• srbenje,
0.6 ml (10 mg/ml) 1 pre-filled syringe with needle guard + 1 alcohol swab pre-filled injector (glass) 0.6 ml (10 mg/ml) 1 pre-filled injector + 1 alcohol swab 
1 napolnjena injekcijska brizga s ščitnikom igle + 1 alkoholni zloženec
Pack size pre-filled syringe (glass) with needle guard 
Velikost pakiranja napolnjena injekcijska brizga (steklena) s ščitnikom igle napolnjen injektor (steklen)
It is available as white, oval tablets (75, 150 and 300 mg). 
Na voljo je v obliki belih ovalnih tablet (75, 150 in 300 mg).
The main benefit was on the effect on blood creatinine levels. 
Glavna korist je bila učinek na ravni kreatinina v krvi.
Its use in combination with hydrochlorothiazide was also examined in 1,736 patients. 
Proučevali so tudi njegovo uporabo v kombinaciji s hidroklorotiazidom pri 1 736 bolnikih.
Irbesartan BMS is not recommended for use in patients below 18 years of age, because of a lack of information on safety and effectiveness in this age group. 
Uporaba zdravila Irbesartan BMS pri bolnikih, mlajših od 18 let, zaradi pomanjkanja informacij o varnosti in učinkovitosti v tej starostni skupini ni priporočljiva.
The European Commission granted a marketing authorisation valid throughout the EU for Irbesartan BMS to Bristol-Myers Squibb Pharma EEIG on 19 January 2007. 
Evropska komisija je dovoljenje za promet z zdravilom Irbesartan BMS, veljavno po vsej Evropski uniji, odobrila družbi Bristol-Myers Squibb Pharma EEIG dne 19. januarja 2007.
When used with hydrochlorothiazide, the effects of the two medicines were additive. 
Pri njegovi sočasni uporabi s hidroklorotiazidom je učinek obeh zdravil aditiven.
If the blood pressure is not sufficiently controlled, the dose can be increased to 300 mg a day or other medicines for hypertension can be added, such as hydrochlorothiazide. 
Če krvni tlak ni zadostno nadzorovan, se odmerek lahko poveča na 300 mg dnevno ali doda drugo zdravilo za zdravljenje povišanega krvnega tlaka, kot je denimo hidroklorotiazid.
The main measure of effectiveness was the reduction in diastolic blood pressure (the blood pressure measured between two heartbeats). 
Glavno merilo učinkovitosti je bilo znižanje „diastoličnega“ krvnega tlaka (krvnega tlaka, merjenega med dvema utripoma srca).
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) IRBESARTAN BMS EPAR summary for the public 
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) IRBESARTAN BMS Povzetek EPAR za javnost
Irbesartan BMS was used for two years or more. 
Zdravilo Irbesartan BMS so bolniki jemali dve leti ali več.
Other information about Irbesartan BMS: 
Druge informacije o zdravilu Irbesartan BMS:
Irbesartan BMS should not be used in people who may be hypersensitive (allergic) to irbesartan or any of the other ingredients. 
Zdravila Irbesartan BMS ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) irbesartan ali katero koli drugo sestavino zdravila.
The active substance in Irbesartan BMS, irbesartan, is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II. 
Zdravilna učinkovina v zdravilu Irbesartan BMS, irbesartan, je „antagonist receptorjev angiotenzina II“, kar pomeni, da v telesu preprečuje delovanje hormona, imenovanega angiotenzin II.
Irbesartan BMS is used in patients who have essential hypertension (high blood pressure). 
Zdravilo Irbesartan BMS se uporablja pri bolnikih, ki imajo esencialno hipertenzijo (visok krvni tlak).
Irbesartan BMS was compared with placebo (a dummy treatment) in 712 patients and with other medicines for hypertension (atenolol, enalapril or amlodipine) in 823 patients. 
Zdravilo Irbesartan BMS so primerjali s placebom (zdravilom brez zdravilne učinkovine) pri 712 bolnikih in drugimi zdravili za zdravljenje visokega krvnega tlaka (atenolol, enalapril, amlodipin) pri 823 bolnikih.
For the treatment of kidney disease, Irbesartan BMS was studied in two large studies involving a total of 2,326 patients with type 2 diabetes. 
Zdravilo Irbesartan BMS so glede zdravljenja ledvične bolezni proučevali v okviru dveh obsežnih študij, ki sta vključevali skupno 2 326 bolnikov s sladkorno boleznijo tipa 2.
In this study, Irbesartan BMS was compared with placebo and with amlodipine. 
V tej študiji so zdravilo Irbesartan BMS primerjali s placebom in amlodipinom.
Irbesartan BMS is a medicine that contains the active substance irbesartan. 
Irbesartan BMS je zdravilo, ki vsebuje zdravilno učinkovino irbesartan.
In addition, more than 1 patient in 100 with type 2 diabetes and kidney disease has the following side effects: hyperkalaemia (high blood potassium levels), orthostatic dizziness (dizziness when standing up), orthostatic hypotension (low blood pressure when standing up) and musculoskeletal (joint) pain. 
Poleg tega so se pri več kot 1 bolniku od 100, ki so imeli sladkorno bolezen tipa 2 in ledvično bolezen, pojavili naslednji neželeni učinki: hiperkaliemija (visoke ravni kalija v krvi), ortostatska omotica (omotica v stoječem položaju), mišičnoskeletne bolečine (bolečine v sklepih) in ortostatska hipotenzija (nizek krvni tlak v stoječem položaju).
The Committee recommended that Irbesartan BMS be given marketing authorisation. 
Odbor je priporočil, da se za zdravilo Irbesartan BMS odobri dovoljenje za promet.
What benefit has Irbesartan BMS shown during the studies? 
Kakšne koristi je zdravilo Irbesartan BMS izkazalo med študijami?
The most common side effects with Irbesartan BMS (seen in more than 1 and 10 patients in 100) are dizziness, nausea (feeling sick) or vomiting, fatigue (tiredness) and increases in blood creatine kinase levels (an enzyme found in muscles). 
Najpogostejši neželeni učinki zdravila Irbesartan BMS (opaženi pri 1 do 10 bolnikih izmed 100) so omotica, navzeja (občutek slabosti) ali bruhanje, utrujenost in povečane ravni kreatin kinaze v krvi (encima, ki ga najdemo v mišicah).
Irbesartan BMS is taken by mouth, with or without food. 
Zdravilo Irbesartan BMS se zaužije peroralno, s hrano ali brez nje.
One study looked at markers of kidney damage by measuring whether the kidneys were releasing the protein albumin into the urine. 
Prva študija je proučevala označevalce poškodb ledvic, in sicer na podlagi merjenja, ali ledvice izločajo v urin beljakovino albumin.
A starting dose of 75 mg can be used in patients receiving haemodialysis (a blood clearance technique) or in patients over 75 years of age. 
Pri bolnikih na hemodializi ali pri bolnikih, starejših od 75 let, se lahko uporabi začetni odmerek 75 mg.
Irbesartan BMS is also used to treat kidney disease in patients with hypertension and type 2 diabetes (non-insulin-dependent diabetes). 
Zdravilo Irbesartan BMS se uporablja tudi za zdravljenje ledvične bolezni pri bolnikih s hipertenzijo in sladkorno boleznijo tipa 2 (sladkorno boleznijo, ki je neodvisna od insulina).
The second study looked at whether Irbesartan BMS increased the time taken until the patients' blood creatinine levels had doubled (a marker of kidney disease), until they needed a kidney transplant or dialysis, or until they died. 
Druga študija je proučevala, ali zdravilo Irbesartan BMS podaljša čas, v katerem se raven kreatinina v krvi (označevalca ledvične bolezni) pri bolnikih podvoji, ali čas do pojava potrebe po presaditvi ledvic ali dializi oziroma do nastopa smrti.
What is the risk associated with Irbesartan BMS? 
Kakšna tveganja so povezana z zdravilom Irbesartan BMS?
In the first kidney disease study, Irbesartan BMS was more effective than placebo at reducing the risk of developing kidney damage as measured by protein excretion. 
V prvi študiji ledvične bolezni je bilo zdravilo Irbesartan BMS učinkovitejše od placeba pri zmanjševanju tveganja za razvoj poškodbe ledvic, merjene na podlagi izločanja beljakovin.
In patients with hypertension and type 2 diabetes, Irbesartan BMS is added to other treatments for hypertension. 
Pri bolnikih z visokim krvnim tlakom in s sladkorno boleznijo tipa 2 se zdravilo Irbesartan BMS uvede poleg drugih načinov zdravljenja hipertenzije.
In the blood pressure studies, Irbesartan BMS was more effective than placebo at reducing diastolic blood pressure and had similar effects to the other medicines for hypertension. 
V študijah krvnega tlaka je bilo zdravilo Irbesartan BMS pri zniževanju diastoličnega krvnega tlaka učinkovitejše od placeba in je imelo podobne učinke kot druga zdravila za zdravljenje povišanega krvnega tlaka.
The Committee for Medicinal Products for Human Use (CHMP) decided that Irbesartan BMS's benefits are greater than its risks for the treatment of essential hypertension and of renal disease in patients with hypertension and type 2 diabetes mellitus. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Irbesartan BMS pri zdravljenju esencialne hipertenzije in ledvične bolezni pri bolnikih z visokim krvnim tlakom in sladkorno boleznijo tipa 2 večje od z njim povezanih tveganj.
Irbesartan BMS was originally studied in 11 trials for its effects on blood pressure. 
Učinke zdravila Irbesartan BMS na krvni tlak so prvotno proučevali v 11 preskušanjih.
The full EPAR for Irbesartan BMS is available here. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Irbesartan BMS je na voljo tukaj.
Why has Irbesartan BMS been approved? 
Zakaj je bilo zdravilo Irbesartan BMS odobreno?
For the full list of all side effects reported with Irbesartan BMS, see the Package Leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Karvea, glejte navodilo za uporabo.
In the second kidney disease study, Irbesartan BMS reduced the relative risk of a doubling of blood creatinine levels, needing a kidney transplant or dialysis, or death during the study by 20% in comparison with placebo. 
V drugi študiji ledvične bolezni je zdravilo Irbesartan BMS v primerjavi s placebom za 20 % zmanjšalo relativno tveganje za podvojitev ravni kreatinina v krvi, za pojav potrebe po presaditvi ledvic ali za nastop smrti med študijo.
How has Irbesartan BMS been studied? 
Kako je bilo zdravilo Irbesartan BMS raziskano?
What is Irbesartan BMS? 
Kaj je zdravilo Irbesartan BMS?
How does Irbesartan BMS work? 
Kako zdravilo Irbesartan BMS deluje?
How is Irbesartan BMS used? 
Kako se zdravilo Irbesartan BMS uporablja?
What is Irbesartan BMS used for? 
Za kaj se zdravilo Irbesartan BMS uporablja?
The review was initiated at the request of the European Commission on 7 May 2015, under Article 31 of Directive 2001/83/EC. 
Pregled se je zaičel 7. maja 2015 na zahtevo Evropske komisije v skladu s členom 31 Direktive 2001/83/ES.
• Patients who have any concerns should discuss them with their doctor or other healthcare professional. 
• Bolniki, ki so v skrbeh, naj se o tem pogovorijo s svojim zdravnikom ali drugim zdravstvenim delavcem.
Commission Decision dates: 29/06/2016 (nationally authorised products), 24/06/2016 (Relvar Ellipta, Revinty Ellipta), 04/07/2016 (BiResp Spiromax, DuoResp Spiromax), 06/07/2016 (Budesonide/Formoterol Teva, Vylaer Spiromax). 
Datumi sklepa komisije: 29. junij 2016 (nacionalno odobrena zdravila), 24. junij 2016 (Relvar Ellipta, Revinty Ellipta), 4. julij 2016 (BiResp Spiromax, DuoResp Spiromax), 6. julij 2016 (Budesonide/Formoterol Teva, Vylaer Spiromax).
Corticosteroid-containing medicines have been authorised in the EU through both central and national approval procedures. 
Zdravila, ki vsebujejo kortikosteroide, so bila v EU odobrena po centraliziranih in nacionalnih postopkih odobritve.
They are similar to natural hormones normally produced by the adrenal glands (two small glands located above the kidneys). 
Podobni so naravnim hormonom, ki jih običajno tvorita nadledvični žlezi (dve majhni žlezi nad ledvicama).
They should not stop using their inhaler or change the way they use it without consulting their prescriber. 
Inhalatorja ne smejo prenehati uporabljati, prav tako ne smejo spremeniti načina uporabe zdravila brez posvetovanja s svojim zdravnikom, ki jim je predpisal zdravilo.
The review confirmed the risk of pneumonia with these products, which has been known for many years, and that it is common (can affect between 1 and 10 COPD patients in 100 using these medicines). 
Pregled je pri teh zdravilih potrdil tveganje za pljučnico, ki je znano že vrsto let in je pogosto (prizadene lahko od 1 do 10 bolnikov s KOPB od 100, ki uporabljajo ta zdravila).
• There is some evidence of an increased risk of pneumonia with increasing steroid dose but this has not been demonstrated conclusively across all studies. 
• Obstajajo nekateri dokazi o povečanem tveganju za pljučnico pri povečevanju odmerka steroida, vendar to ni bilo nesporno dokazano v vseh študijah.
They are usually taken using inhalers which either contain a corticosteroid alone or a corticosteroid in combination with another medicine (such as a long-acting beta2 agonist that widens the airways). 
Običajno se jemljejo z uporabo inhalatorjev, ki vsebujejo samo kortikosteroid ali kortikosteroid v kombinaciji z drugim zdravilom (npr. dolgodelujočim agonistom beta2, ki širi dihalne poti).
• The Agency's review included published data from randomised controlled clinical trials and a number of meta-analyses, as well as observational studies. 
• V pregled agencije so bili vključeni objavljeni podatki iz randomiziranih kontroliranih kliničnih raziskav, večjega števila metaanaliz in opazovalnih študij.
Corticosteroids, also known as steroids, are anti-inflammatory medicines used for a wide range of conditions. 
Kortikosteroidi, znani tudi kot steroidi, so protivnetna zdravila, ki se uporabljajo pri zdravljenju številnih bolezni.
• Patients need to alert their doctors if they start to get symptoms that suggest they are developing pneumonia, so that it can be identified and treated early. 
• Bolniki naj svoje zdravnike opozorijo, če se pojavijo simptomi, ki kažejo, da se razvija pljučnica, tako da jo bo mogoče zgodaj prepoznati in zdraviti.
No clinical trials directly examined the risk of pneumonia with ICS head to head, and only indirect comparison in metaanalyses/systematic reviews or from observational studies is available. 
V nobenem kliničnem preskušanju niso z neposredno primerjavo preučevali tveganja za pljučnico pri različnih IKS; na voljo so samo posredne primerjave iz metaanaliz/sistematičnih pregledov ali opazovalnih študij.
Overall the benefits of inhaled corticosteroid medicines in treating COPD continue to outweigh their risks and there should be no change to the way in which these medicines are used. 
Koristi inhalacijskih kortikosteroidnih zdravil pri zdravljenju KOPB v splošnem še naprej presegajo tveganja in načina njihove uporabe ni treba na noben način spreminjati.
• Patients should be advised to report any increased breathing difficulties or other symptoms suggestive of infection. 
• Bolnikom je treba svetovati, naj sporočijo vsakršne težave z dihanjem ali druge simptome, ki kažejo na okužbo.
Beclomethasone, budesonide, flunisolide, fluticasone propionate and fluticasone furoate are corticosteroids authorised and marketed as inhalation formulations for use in COPD. 
Beklometazon, budezonid, flunizolid, flutikazonpropionat in flutikazonfuroat so kortikosteroidi, ki so odobreni in se tržijo kot inhalacijski pripravki za zdravljenje KOPB.
Due to the variability in the clinical data and multiple uncertainties with study methodologies, this does not provide conclusive evidence for intra-class differences in the magnitude of risk. 
Zaradi variabilnosti kliničnih podatkov in več z metodami proučevanja povezanih negotovosti ni nespornih kliničnih dokazov za razlike med velikostmi tveganja v skupini.
These symptoms can be like those of an exacerbation (an episode of worsening COPD) and include fever or chills, increased amounts of mucus (phlegm) or a change in its colour, or worsening of cough or breathing difficulties. 
Simptomi so podobni simptomom poslabšanja (epizoda poslabšanja KOPB) in vključujejo povišano telesno temperaturo ali mrzlico, povečano količino sluzi (izmečka) ali spremembo njegove barve in poslabšanje kašlja ali težave z dihanjem.
The review was carried out by the Agency's Pharmacovigilance Risk Assessment Committee (PRAC), which recommended that the product information for these medicines should be updated to adequately reflect current knowledge about the risks. 
Pregled je izvedel Odbor za oceno tveganja na področju farmakovigilance (PRAC), ki je priporočil, naj se informacije o zdravilu za ta zdravila posodobijo, da bodo primerno podajala sedanje vedenje o tveganjih.
• The product information for all medicines of the class will be updated to reflect current knowledge about pneumonia risk. 
• Informacije o zdravilu bodo pri vseh zdravilih te skupine posodobljene, da bodo podajale sedanje vedenje o tveganju za pljučnico.
Patients with COPD and their doctors should however be alert for signs and symptoms of pneumonia, bearing in mind that the clinical features of pneumonia overlap with those of a worsening (exacerbation) of the underlying disease. 
Bolniki s KOPB in njihovi zdravniki naj bodo kljub temu pozorni na znake in simptome pljučnice, pri čemer naj upoštevajo, da se klinične značilnosti pljučnice prekrivajo z značilnostmi poslabšanja (eksacerbacije) osnovne bolezni.
• EMA has reviewed the risk of pneumonia in COPD patients using corticosteroid inhalers and has concluded that this risk applies to all medicines of this class. 
• Agencija EMA je pregledala tveganje za pljučnico pri bolnikih s KOPB, ki uporabljajo kortikosteroidne inhalatorje, in zaključila, da je tveganje prisotno pri vseh zdravilih te skupine.
In the EU, the available products include the active substances beclomethasone, budesonide, flunisolide, fluticasone furoate or fluticasone propionate. 
Zdravila, ki so dostopna v EU, vsebujejo zdravilne učinkovine beklometazon, budezonid, flunizolid, flutikazonfuroat in flutikazonpropionat.
COPD is a long-term disease of the lungs in which the airways and air sacs in the lungs become damaged or blocked, leading to breathing difficulties. 
KOPB je dolgotrajna bolezen pljuč, pri kateri so dihalne poti in zračni mešički v pljučih poškodovani ali blokirani, zaradi česar je dihanje oteženo.
• It has been known for some time that inhaled corticosteroid medicines increase the risk of pneumonia (infections of the lungs) in patients taking these medicines for the long-term lung disease COPD (chronic obstructive pulmonary disease). 
• Že nekaj časa je znano, da inhalacijska kortikosteroidna zdravila povečajo nevarnost pljučnice (okužbe pljuč) pri bolnikih, ki ta zdravila jemljejo zaradi dolgotrajne pljučne bolezni KOPB (kronična obstruktivna pljučna bolezen).
• Corticosteroid inhalers reduce inflammation and swelling in the lungs and so help breathing in patients with COPD. 
• Kortikosteroidni inhalatorji zmanjšujejo vnetje in otekanje pljuč in s tem pomagajo bolnikom s KOPB pri dihanju.
The CHMP opinion was forwarded to the European Commission, which issued a final legally binding decision applicable in all EU Member States. 
Mnenje odbora CHMP je bilo predloženo Evropski komisiji, ki je izdala končni pravno zavezujoč sklep, ki velja za vse države članice EU.
On 28 April 2016 EMA completed a review of the known risk of pneumonia (lung infection) in patients who take inhaled corticosteroid medicines to treat chronic obstructive pulmonary disease (COPD). 
Dne 28. aprila 2016 je agencija EMA zaključila pregled znanega tveganja za pljučnico (okužbo pljuč) pri bolnikih, ki prejemajo inhalacijska kortikosteroidna zdravila za zdravljenje kronične obstruktivne pljučne bolezni (KOPB).
The CHMP's opinion was then sent to the European Commission, which issued a final legally-binding decision valid throughout the EU. 
Mnenje odbora CHMP je bilo nato posredovano Evropski komisiji, ki je izdala pravno zavezujoč sklep, veljaven v vsej EU.
When taken by inhalation they attach to receptors in the airways and cause a reduction in lung inflammation, which makes breathing easier. 
Pri inhalaciji se pritrdijo na receptorje v dihalnih poteh in zavrejo pljučno vnetje, s čimer postane dihanje lažje.
• Following a review of the available data, EMA has confirmed the risk of pneumonia with inhaled corticosteroids (ICS) in patients with COPD. 
• Po pregledu razpoložljivih podatkov je agencija EMA potrdila tveganje za pljučnico pri uporabi inhalacijskih kortikosteroidov (IKS) pri bolnikih s KOPB.
The PRAC recommendations were sent to the Committee for Medicinal Products for Human Use (CHMP), which adopted the Agency's opinion. 
Priporočila odbora PRAC so bila poslana Odboru za zdravila za uporabo v humani medicini (CHMP), ki je sprejel končno mnenje agencije.
• Healthcare professionals should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of such infections overlap with the symptoms of COPD exacerbations. 
• Pri bolnikih s KOPB naj zdravstveni delavci ostanejo pozorni na morebiten razvoj pljučnice, saj se klinične značilnosti takih okužb prekrivajo s simptomi poslabšanj KOPB.
The review has been carried out by the Pharmacovigilance Risk Assessment Committee (PRAC), the Committee responsible for the evaluation of safety issues for human medicines, which made a set of recommendations. 
Pregled je opravil Odbor za oceno tveganja na področju farmakovigilance (PRAC), ki je odgovoren za presojo varnostnih vprašanj o zdravilih za uporabo v humani medicini, in podal več priporočil.
The evidence did not confirm any differences in risk between products. 
Dokazi niso potrdili razlik v tveganju med zdravili.
Corticosteroid inhalers are widely used in the European Union (EU) to treat COPD and pneumonia is a common side effect of such treatment. 
Inhalacijski kortikosteroidi se v Evropski uniji (EU) pogosto uporabljajo za zdravljenje KOPB.
The review did not find any conclusive evidence of differences in this risk for different products. 
Pregled ni prinesel prepričljivih dokazov o razlikah v tveganju med različnimi zdravili.
Review finds no differences between products in risk of pneumonia 
Pregled ni pokazal razlik med zdravili glede tveganja za pljučnico.
There is no conclusive clinical evidence for intra-class differences in the magnitude of the risk among ICS products. 
Za razlike med velikostmi tveganja med zdravili iz skupine IKS ni nobenih trdnih kliničnih dokazov.
Both populations received multivitamin supplements. 
Obe populaciji sta prejemali multivitaminske dodatke.
It is not known whether these findings translate into long-term clinical benefits. 
Ni znano, ali te ugotovitve pomenijo dolgoročno klinično korist.
Diverticulitis. 
Divertikulitis.